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Abstract
Introduction We have shown previously that treatment with
pegylated leptin peptide receptor antagonist 2 (PEG-LPrA2)
reduced the expression of vascular endothelial growth factor
(VEGF), vascular endothelial growth factor receptor type 2
(VEGFR2) and growth of 4T1-breast cancer (BC) in syngeneic
mice. In this investigation, PEG-LPrA2 was used to evaluate
whether the inhibition of leptin signaling has differential impact
on the expression of pro-angiogenic and pro-proliferative
molecules and growth of human estrogen receptor-positive
(ER+) and estrogen receptor-negative (ER-) BC xenografts
hosted by immunodeficient mice.
Methods To test the contribution of leptin signaling to BC
growth and expression of leptin-targeted molecules, PEG-
LPrA2 treatment was applied to severe immunodeficient mice
hosting established ER+  (MCF-7 cells; ovariectomized/
supplemented with estradiol) and ER- (MDA-MB231 cells) BC
xenografts. To further assess leptin and PEG-LPrA2 effects on
ER+ and ER- BC, the expression of VEGF and VEGFR2 (protein
and mRNA) was investigated in cell cultures.
Results PEG-LPrA2 more effectively reduced the growth of
ER+ (>40-fold) than ER- BC (twofold) and expression of pro-
angiogenic (VEGF/VEGFR2, leptin/leptin receptor OB-R, and
IL-1 receptor type I) and pro-proliferative molecules
(proliferating cell nuclear antigen and cyclin D1) in ER+ than in
ER- BC. Mouse tumor stroma in ER+ BC expressed high levels
of VEGF and leptin that was induced by leptin signaling. Leptin
upregulated the transcriptional expression of VEGF/VEGFR2 in
MCF-7 and MDA-MB231 cells.
Conclusions These results suggest that leptin signaling plays
an important role in the growth of both ER+ and ER- BC that is
associated with the leptin regulation of pro-angiogenic and pro-
proliferative molecules. These data provide support for the
potential use of leptin-signaling inhibition as a novel treatment
for ER+ and ER- BC.
Introduction
Leptin is a small nonglycosylated protein (16 kDa) product of
the ob gene. White adipose tissue is the primary source of lep-
tin in benign tissue, but leptin is also expressed and secreted
by cancer cells [1]. Leptin exclusively binds to its receptor,
OB-R. Several isoforms of OB-R are found in diverse tissues
and in cancer cells including the long isoform, OB-Rb [2,3].
Upon leptin activation, the OB-R isoforms can utilize a number
of diverse signaling pathways relevant to cancer growth [4,5].
The well-documented biological actions of leptin at the
BC: breast cancer; bp: base pairs; BSA: bovine serum albumin; ELISA: enzyme-linked immunosorbent assay; ER: estrogen receptor; IL: interleukin-
1; IL-1R tI: interleukin-1 receptor type I; MT: mammary tumor; OB-R: leptin receptor; PBS: phosphate-buffered saline; PCNA: proliferating cell nuclear 
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hypothalamic level occur through OB-Rb signals that are
linked to the control of appetite and energy balance [4].
Evidence is mounting to support the idea that leptin is the link
between obesity and the higher incidence of a variety of can-
cers [6,7]. Several studies show that conditions characterized
by high levels of leptin (female gender, obesity, menopause)
are positively correlated with a higher incidence of breast can-
cer (BC) [8-10]. For BC patients, obesity can be an indicator
of a poor prognosis even after the administration of adjuvant
chemotherapy [6,7]. Nevertheless, there are contradicting
reports showing no association between serum levels of leptin
in premenopausal or postmenopausal women and the risk of
BC [11,12]. Leptin and OB-R levels, however, are higher in
BC cells than in normal mammary cells [13,14].
Almost all BC cells can develop metastases. This depends on
the intricate relations of numerous tumor cell factors that
include location and extension of cancer, the type and differ-
entiation of the tumor cells, as well as other only incompletely
understood factors. A role for the mammary fat pad in mam-
mary gland development and enhancement of the growth and
ability to metastasize BC cells has been described. Cytokines,
the tumor microenvironment, adipose tissue, and the tissue
microenvironment in remote organs could contribute to prime
BC cells, promoting metastasis. Among these factors, TNFα
and IL-1 are potent leptin inducers in adipose tissue [15]. The
majority of BC cells express estrogen receptor (ER) and their
growth is mainly driven by ER signaling [16] that could also be
activated by leptin signaling [17-19]. A high level of OB-R in
BC is a significant risk factor, independent of ER expression
and other risk factors [13]. Moreover, there is significant cor-
relation between the levels of leptin/OB-R in BC and a higher
incidence of BC metastatic disease, poor prognosis, and
lower survival rate of BC patients [13,14]. Leptin signaling
could play an important role in the growth of highly invasive,
metastatic, and more deadly estrogen receptor-negative (ER-)
BC cells that do not respond to endocrine therapy and are
mostly treated with chemotherapeutics that exhibit several det-
rimental side effects [20].
Leptin's pleiotropic effects are linked to diverse processes that
if de-regulated could contribute to the growth of cancer; that
is, proliferation, anti-apoptosis, angiogenesis, extracellular
membrane component changes and metastasis [21-24]. Lep-
tin enhances the expression of cell cycle regulators cdk-2 and
cyclin D1 in human BC cells [22,23] and of pro-angiogenic fac-
tors in mouse mammary [24] and endometrial cancer cells [3].
Furthermore, leptin signaling is related with an increase cell
survival since it can upregulate the expression of the anti-
apoptotic protein, Bcl-2 [25-27]. Leptin's pleiotropic actions
may therefore impact the growth of cancer through a variety of
mechanisms. Hence, leptin may play an important role in con-
trolling the proliferation, survival, and migration of cells
involved in cancer growth. A recent published study by Perera
and colleagues has reinforced this idea, showing data sup-
porting leptin promotion of mammary tumor (MT) growth
through multiple mechanisms, including regulating the cell
cycle, apoptosis, and modulating the extracellular environment
[28]. Little is known, however, about the exact mechanism(s)
by which leptin contributes to tumor progression.
Data from animal studies reinforced the idea that leptin can
contribute to BC growth. Obese rodents have a higher inci-
dence of MTs than lean controls [29]. In contrast, obese mice
with deficiency of leptin-signaling (ob/ob and db/db) have a
significantly lower incidence of MT than their lean littermates
[30,31]. Furthermore, nonobese mouse mammary tumor virus/
human transforming growth factor-alpha mice have a high rate
of MT development [29], which is offset in the offspring when
they are crossed with leptin-signaling-deficient mice [30,31].
We previously reported that the blockade of leptin actions in
mice hosting syngeneic MTs delayed tumor onset and
reduced tumor growth [24]. Well known, however, is the fact
that BC has diverse genetic and phenotypic heterogeneity. No
single animal model can therefore fully represent all of the pos-
sible pathways by which human BC develops or progress.
The aim of the present study was to evaluate the impact of lep-
tin-signaling inhibition on the growth of human BC xenografts
and their expression of leptin-targeted molecules. Based on
the reported leptin-mediated overexpression of aromatase
[18] and transactivation of ER [19] in MCF-7 cells, we hypoth-
esized that the effects of pegylated leptin peptide receptor
antagonist 2 (PEG-LPrA2) on the growth of human BC
xenografts will be more evident in MCF-7 ER+ BC than in
MDA-MB231 ER- BC. This study shows that leptin signaling
plays an important role in the growth of both ER+ and ER-
human BC xenografts; ER+ BC cells, however, were more
responsive to PEG-LPrA2 treatment. Leptin signaling regu-
lates the expression of angiogenic and pro-proliferative factors
in BC and tumor stroma. The leptin tumor-promoting effects
are probably direct (cell proliferation and survival) and indirect
via the regulation of molecules involved in tumor growth. Col-
lectively, these results strongly suggest that inhibition of leptin
signaling may have potential novel therapeutic value for con-
trolling ER+ and ER- BC growth.
Materials and methods
Antibodies and reagents
Antibodies for human vascular endothelial growth factor
(VEGF) (A-20), for vascular endothelial growth factor receptor
type 2 (VEGFR2) (Flk-1 or KDR; A-3), for cyclin D1 (HD11), for
human IL-1 receptor type I (IL-1R tI) (N-20, proliferating cell
nuclear antigen (PCNA); FL-261), for ERα (MC-20), for leptin
(Y-20), for human OB-Rb (long isoform intracellular COOH
end; C-20) and for cytokeratin 8/18 (0.N.352), blocking pep-
tide antibody for competition studies, positive controls, protein
G-agarose and the rabbit/goat ABC staining kit were obtained
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).Available online http://breast-cancer-research.com/content/11/3/R36
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β-Actin antibody (ab8226) was purchased from Abcam Inc.
(Cambridge, MA, USA). RPMI-1640 medium was obtained
from American Type Culture Collection (Manassas, VA, USA).
Fetal bovine serum was obtained from Gemini Bioproducts
(Woodland, CA, USA), and antibiotic-antimycotic mixtures
were purchased from Gibco BRL Products (Gaithersburg,
MD, USA). Succinimidyl propionate polyethylene glycol (20
kDa) was obtained from Nektar Therapeutics (Huntsville, AL,
USA). Other chemicals were obtained from Sigma Inc. (St
Louis, MO, USA).
Leptin peptide receptor antagonist
Leptin receptor antagonist 2 and a scrambled peptide for con-
trol were synthesized and purified as described elsewhere
[32]. To increase their bioavailability, the peptides were cova-
lently bound to succinimidyl propionate polyethylene glycol
(20 kDa; half-life > 60 hours) at 5:1 molecular ratios (leptin
receptor antagonist 2:polyethylene glycol) in PBS (pH 7.0),
following the manufacturer's instructions (Nektar Therapeu-
tics). In contrast to unconjugated leptin receptor antagonist
peptides, their polyethylene glycol derivatives are water-solu-
ble.
Cell culture
The human BC adenocarcinoma cell lines MCF-7 (ER+) and
MDA-MB231 (ER-) (American Type Culture Collection) were
cultured (1.5 × 105 cells/well; duplicate wells; experiments
repeated, n = 3) on uncoated flat-bottomed plastic 12-well
plates with complete growth medium (American Type Culture
Collection). Semi-confluent cells were cultured for 48 hours in
basal medium (without fetal bovine serum) containing leptin (0,
0.6, 1.2 and 6.25 nM, equivalent to 0, 10, 20, and 100 ng/ml)
and/or PEG-LPrA2 and inert control, pegylated scrambled
peptide (Sc-PEG) (5 mM dissolved in water; final concentra-
tion in the medium, 3 μM). Conditioned media were harvested
and cells were lysed as described elsewhere [24]. Protein
concentrations were determined by the Bio-Rad kit (Bio-Rad
Lab., Hercules, CA, USA).
Real-time RT-PCR
Total RNA was extracted, purified from cells (RNeasy and
RNase-Free DNase Set; Qiagen Inc., Valencia, CA, USA) and
quantified (Quanti-iT RNA Assay Kit/Qubit fluorometer; Invitro-
gen, Carlsbad, CA, USA). cDNA was synthesized using the
iScript cDNA kit (Bio-Rad) and a control without RT was used
for each reaction to exclude chromosomal DNA contamina-
tion. cDNA samples were analyzed by real-time PCR using IQ
SYBR Green Supermix (Bio-Rad). Relative expression values
R were calculated using 18S rRNA as reference (n = 3):
The sequences of primers for human VEGF mRNA (180 bp
DNA fragment), VEGFR2 (Flk1) mRNA (114 bp fragment) and
18S rRNA (317 bp DNA fragment) are available upon request.
The PCR conditions were as follows: one cycle, 95°C for 3
minutes; and 45 cycles, 95°C for 30 seconds, 52°C for 30
seconds and 72°C for 30 seconds.
Therapeutic treatment to mice hosting established 
breast cancer xenografts
All animal studies were approved by the Morehouse School of
Medicine Institutional Review Board. Ovariectomized and non-
ovariectomized NOD.CB17-Prkdcscid/NCrCrl (SCID) mice, 6
weeks old, were obtained from Charles River Laboratories
(Wilmington, MA, USA). Ovariectomized mice were subcuta-
neously implanted with an estradiol capsule (2 mg 17β-estra-
diol and 1.6 mg cholesterol) that was replaced every 21 days
to sustain the growth of ER+ BC cells. MCF-7 cells for ovariec-
tomized mice or MDA-MB231 cells for nonovariectomized
mice (2 × 106 cells/matrigel 4 mg/ml) were orthotopically inoc-
ulated into the mammary fat pads of mice (second row, right
nipple). The tumor take rate was 100% in all experiments.
Before treatment, the ovariectomized mice hosting MCF-7 BC
were slightly heavier than those nonovariectomized mice host-
ing MDA-MB231. Once tumors reached an approximate vol-
ume of 100 mm3 (measured with a caliper; π/6 × width2 ×
length), 10 mice/group hosting MCF-7 ER+ BC and MDA-
MB231 ER- BC were randomly allocated to two groups per
tumor type such that their tumor size and body weight were
similar. The mice were then treated with PEG-LPrA2 for leptin-
signaling inhibition or with inert Sc-PEG for controls, both 50
μl/0.5 mM in PBS every 48 hours, given by intravenous injec-
tion. Because the PEG-LPrA2 half-life is about 60 hours, this
schedule will ensure a continuous plasma level of the antago-
nist. Treatments ended after 18 days. After 8 hours of fasting
and before euthanasia, blood was drawn from the retro-orbital
vein of mice (mild anesthesia; 400 μl avertin, 200 mg/kg body
weight) for VEGF and leptin determinations [24].
Mammary tumor growth
Changes in MT size were determined by caliper measure-
ments on a weekly basis. Tumors were dissected and weighed
after euthanasia. The impact of treatment on general health,
body weight, and food intake was recorded weekly. Carcass
weight was determined post mortem.
Leptin targets in mammary tumors
Immunoprecipitation/western blot
The levels of VEGF, VEGFR2, OB-Rb, cyclin D1, and PCNA in
tumor lysates were determined by immunoprecipitation/west-
ern blot. Briefly, protein concentrations in lysates from cell cul-
tures and MTs were determined by the Bradford method (Bio-
Rad). Thirty micrograms of protein were analyzed by western
blot either directly or after immunoprecipitation with protein A
or protein G-agarose beads following the manufacturer's
instructions (Pierce, Rockford, IL, USA). Antibodies against β-
actin were used as loading controls. Nonspecific mouse, rab-
bit, and goat IgGs were used as negative controls for western
R = −− 2 () ΔΔ Ct   t arget C t   r ef er enceBreast Cancer Research    Vol 11 No 3    Rene Gonzalez et al.
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blot analysis. For quantitative evaluation of antigen expression,
the blots were scanned and analyzed by the NIH Image pro-
gram [24,33,34].
Immunohistochemistry
To assess the potential effects of blockade of OB-R function
in vivo on the expression of various antigens (that is, VEGF,
VEGFR2, OB-Rb, leptin, IL-1R tI, PCNA, and cyclin D1), immu-
nohistochemistry in paraffin block sections (4 μm) was per-
formed. Negative controls were also included. Briefly,
unmasking of tissue antigens was performed by heat treat-
ment in sodium citrate buffer (pH 6, 10 mM) at 95°C for 15
minutes and partial digestion at 37°C for 10 minutes with pro-
tease (Sigma Inc.). After quenching endogenous peroxidase
activity with H2O2 (3% water solution) and blocking (2.5%
horse or rabbit normal serum), tissue sections were incubated
for 1 hour at room temperature with the following primary anti-
bodies diluted in PBS- 0.1% BSA: anti-VEGF, anti-VEGFR2,
anti-OB-Rb, anti-leptin, anti-IL-1R tI, anti-PCNA, and anti-cyc-
lin D1 (all at 1 μg/ml). Monoclonal antibody against cytokeratin
8/18 (dilution 1:100) was routinely used to detect tumor epi-
thelial components. Biotinylated secondary antibodies were
used. The tissues were incubated with a streptavidin-biotin-
peroxidase system according to the manufacturer's directions
(Vectastain, ABC-AP kit; Vector, Burlingame, CA, USA), coun-
terstained with hematoxylin (Dako Corp., Carpinteria, CA,
USA), and mounted with VectaMount (Vector). Negative con-
trols included tissue preparations in which the primary anti-
bodies were substituted by irrelevant species-matched IgG.
Negative controls for competitive studies with primary antibod-
ies were generated by reincubation with their respective
blocking peptides (20 μg/ml; Santa Cruz Biotechnology). All
washing steps were performed by immersion of the prepara-
tions three times in PBS for 5 minutes at room temperature
[24,34].
Vascular endothelial growth factor and leptin 
concentrations
The levels of human and mouse VEGF and leptin in condi-
tioned media from cell cultures, mouse sera, and MT lysates
were determined by ELISA (R&D Systems Inc., Minneapolis,
MN, USA).
Statistical analysis
A one-way analysis of variance test with Dunnett error protec-
tion and confidence interval of 95% was used from the Ana-
lyse-it for Microsoft Excel (Leeds, UK) [35] analysis of in vivo
and in vitro treatments. The experiments were repeated (n =
3) and all samples were analyzed in duplicate. The data were
expressed as mean ± standard error. P < 0.05 was consid-
ered statistically significant. The model included the main
effects of treatments and replicates.
Results
ER+ and ER- breast cancer xenograft growth
Injection of PEG-LPrA2 into mice with established MCF-7 BC
xenografts resulted in a dramatic reduction (>40-fold) in the
growth of tumor explants (Figure 1a). The reduction of MCF-7
tumors by PEG-LPrA2 was significant after 1 week of treat-
ment. Moreover, at the end of treatment (18 days) the tumors
were not palpable, which was confirmed after euthanasia and
dissection of the tumor area. This was in contrast to those
mice receiving control solution, Sc-PEG (Figure 1b). The treat-
ment with PEG-LPrA2 was also effective in reducing MDA-
MB231 BC xenograft growth. Mice hosting established MDA-
MB231 BC had a significant reduction of tumor growth rate
(Figure 1c). At week 3 of PEG-LPrA2-treatment BC, the vol-
ume of MDA-MB231 tumors was decreased approximately
twofold when compared with the control mice (Figure 1c),
which was assessed by a decrease in mass (Figure 1d). MCF-
7 tumor masses from control mice were bigger than those
from MDA-MB231 tumors. This could be due to increased
vascularization in MCF-7 BC in control mice. The MCF-7
tumors were less differentiated (less prominent nucleoli, less
intense chromatin change patterns, non-uniform large cells
encountered together with small cells, and so forth) than those
from MDA-MB231 BC.
Leptin-targeted molecules in breast cancer xenografts
Immunohistochemistry analysis revealed that the levels of lep-
tin, OB-R, human VEGF, VEGFR2 or Flk-1, PCNA, human IL-
1R tI and cyclin D1 were significantly lower in MCF-7 tumors
from mice treated with PEG-LPrA2 than in tumors from Sc-
PEG-treated controls (Figure 2a). Similar results were found in
MDA-MB231-derived MTs from mice treated with PEG-LPrA2
(Figure 2b). Reduction in the expression of these antigens was
more evident, however, in MCF-7 BC than in MDA-MB231 BC
(Figure 2).
The impact of PEG-LPrA2 treatment on proliferation markers
(PCNA and cyclin D1) was further investigated in tumor lysates
by western blot analysis (Figure 3). A significant reduction of
PCNA and cyclin D1 levels was found in MCF-7 BC (Figure
3a) and MDA-MB231 BC (Figure 3b) from mice treated with
PEG-LPrA2.
VEGF/VEGFR2 and leptin/OB-Rb in breast cancer 
xenografts
PEG-LPrA2 treatment significantly decreased the levels of
human VEGF (~15-fold) in MCF-7 BC lysates (Figure 4a).
Plasma levels of human VEGF were low and no significant dif-
ferences were detected between PEG-LPrA2-treated mice
hosting MCF-7 BC when compared with controls (Figure 4a).
Levels of mouse VEGF in MCF-7 BC lysates from control mice
were significantly higher than those for human VEGF. In con-
trast, levels of mouse VEGF in plasma from mice hosting MCF-
7 BC and treated with PEG-LPrA2 were no different from
those from control mice (Figure 4a). Immunoprecipitation/Available online http://breast-cancer-research.com/content/11/3/R36
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western blot analysis showed that VEGF and VEGFR2 levels
were significantly reduced by PEG-LPrA2 in MCF-7 BC when
compared with controls (Figure 4a).
Reduced levels of human VEGF were found in the MDA-
MB231 BC from mice treated with PEG-LPrA2 (Figure 4b).
Immunoprecipitation/western blot analysis showed that PEG-
LPrA2 treatment reduced the levels of VEGFR2 in MDA-
MB231 BC (approximately threefold; Figure 4b). In compari-
son, human VEGF levels in tumor lysates from control mice
hosting MDA-MB231 BC xenografts were significantly higher
(Figure 4b) than in control mice hosting MCF-7 BC xenografts
(Figure 4a). In contrast, stroma in MDA-MB2231 BC from con-
trol mice had lower levels of mouse VEGF (Figure 4b) com-
pared with stroma from MCF-7 BC xenografts hosted by
control mice (Figure 4a).
PEG-LPrA2 treatment reduced the levels of human leptin in
tumors from mice hosting MCF-7 BC xenografts (Figure 4c).
Similarly, the levels of mouse leptin from mice treated with
PEG-LPrA2 were lower than those from control but no differ-
ences were detected in plasma (Figure 4c). In a similar way,
PEG-LPrA2 treatment reduced the levels of human leptin
within MDA-MB231 BC xenografts but tumor levels of mouse
leptin were similar between treated and controls (Figure 4d).
In comparison, MDA-MB231 BC lysates from control mice
exhibited higher levels of human leptin but lower levels of
mouse leptin (Figure 4d) than those from control mice hosting
MCF-7 BC xenografts (Figure 4c). Immunoprecipitation/west-
ern blot analysis revealed a notable reduction of human OB-
Rb expression in MCF-7 and MDA-MB231 BC xenografts in
mice treated with PEG-LPrA2 compared with controls (Figure
4c,d).
Figure 1
Impact of PEG-LPrA2 treatment on growth of estrogen receptor positive and negative breast cancer xenografts Impact of PEG-LPrA2 treatment on growth of estrogen receptor positive and negative breast cancer xenografts. (a) Growth of established MCF-7 
breast cancer (BC) xenografts. (b) Tumor mass of established MCF-7 BC xenografts. (c) Growth of established MDA-MB231 BC xenografts. (d) 
Tumor mass of established MDA-MB231 BC xenografts. Female SCID mice were orthotopically inoculated into the mammary glands with human 
estrogen-receptor-positive MCF-7 (for ovariectomized mice) or estrogen-receptor-negative MDA-MB231 cells (2 × 106). The mice were treated with 
pegylated leptin peptide receptor antagonist 2 (PEG-LPrA2) (n = 10/each cell type) or with pegylated scrambled peptide (control; n = 10/each cell 
type). Ovariectomized mice were supplemented with a subdermal estradiol capsule. Tumor growth was determined using a caliper (tumor volume = 
π/6 × width2 × length). Data expressed as mean ± standard error. *P < 0.05 and **P < 0.01, significant differences with respect to control mice.Breast Cancer Research    Vol 11 No 3    Rene Gonzalez et al.
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General effects of PEG-LPrA2
Overall, PEG-LPrA2 was not toxic and did not affect the
energy balance (body weight, carcass weight or food intake)
of treated mice when compared with control mice hosting
MCF-7 or MDA-MB231 BC xenografts. Significant differ-
ences were found, however, between carcass weights from
mice hosting MCF-7 BC and MDA-MB231 BC (Table 1). An
increased amount of abdominal fat was found in ovariect-
omized mice hosting MCF-7 BC xenografts compared with
those hosting MDA-MB231 BC xenografts. These differences
were found not related to PEG-LPrA2 or control treatments.
PEG-LPrA2 delayed tumor onset and growth, and negatively
impacted on the levels of pro-angiogenic, pro-inflammatory
and pro-proliferative molecules in both types of BC. There
were more notable effects of PEG-LPrA2, however, in mice
hosting MCF-7-derived BC xenografts.
Leptin receptor and estrogen receptor in cancer cell 
cultures
MCF-7 and MDA-MB231 cells expressed OB-R, but only
MCF-7 cells expressed ERα (immunocytochemistry and west-
ern blot; data not shown).
Figure 2
Proliferation, angiogenesis, and inflammation-related molecules in estrogen receptor positive and negative breast cancer xenografts Proliferation, angiogenesis, and inflammation-related molecules in estrogen receptor positive and negative breast cancer xenografts. (a) Estrogen-
receptor-positive MCF-7 breast cancer (BC) and (b) estrogen-receptor-negative MDA-MB231 BC from control (pegylated scrambled peptide) and 
pegylated leptin peptide receptor antagonist 2 (PEG-LPrA2)-treated SCID mice. Pictures show representative results from immunohistochemical 
analysis of pro-proliferative and pro-angiogenic molecules (n = 5; magnification x100). Arrows indicate stronger staining of the antigens in tumors 
from controls than tumors from PEG-LPrA2-treated mice. IL-1R tI, interleukin-1 receptor type I; OB-R, leptin receptor; PCNA, proliferating cell 
nuclear antigen; VEGF, vascular endothelial growth factor; VEGFR2, vascular endothelial growth factor receptor type 2.Available online http://breast-cancer-research.com/content/11/3/R36
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Leptin in cancer cell cultures
MDA-MB231 cells (9.6 pg/ml/mg, equivalent to 0.41 pM)
under basal conditions secreted more leptin (approximately
fourfold) than MCF-7 cells (2.6 pg/ml/mg, equivalent to 0.15
pM).
VEGF and VEGFR2 in cancer cell cultures
Basal secretion of VEGF was much higher from MDA-MB231
(~46-fold; Figure 5b) than from MCF-7 (Figure 5a) cell cul-
tures. Leptin significantly increased the levels of VEGF in
medium of MCF-7 cell cultures at all the leptin doses assayed
(Figure 5a) but had no effects on VEGF levels in MDA-MB231
cell cultures (Figure 5b). Importantly, the co-incubation of
MCF-7 cells with leptin and PEG-LPrA2 completely abrogated
the leptin-mediated increase in VEGF in the conditioned
medium (Figure 5a). Real-time RT-PCR analysis indicated that
leptin upregulates the transcriptional expression of VEGF in
MCF-7 cells (Figure 5a) and in MDA-MB231 cells (Figure 5b).
The co-incubation of cells with leptin and PEG-LPrA2 inhibited
the leptin effects on VEGF mRNA levels. In both types of cells,
leptin in a dose-response manner significantly increased the
levels of VEGFR2, and PEG-LPrA2 abrogated these effects
(Figure 5c,d). Real-time RT-PCR showed that leptin also
increased the expression of VEGFR2 mRNA in both cell types
(Figure 5c,d) that were inhibited by PEG-LPrA2.
Discussion
The present investigation outlines for the first time the contri-
butions of leptin to the growth of human ER+ BC xenografts
and the very aggressive ER- BC hosted by SCID mice. A
potent antagonist for the leptin receptor, PEG-LPrA2 (with an
extended half-life of 60 hours), was used to test the impact of
leptin signaling inhibition on the growth of BC and the expres-
sion of leptin-targeted molecules important for BC angiogen-
esis and proliferation. It is well known that while there are
significant strengths in the use of this mouse model that does
not reject human BC cells, there also are limitations – includ-
ing the lack of the physiological immune reaction to the distur-
bance of leptin's inflammatory functions that may influence the
prediction of a BC patient's response to this therapy. To have
an idea of how human BC could respond to PEG-LPrA2, how-
ever, it was necessary to use human BC growing in SCID
mice. The significance of leptin-induced signaling in the regu-
lation of VEGF and VEGFR2 expression (at protein and mRNA
levels) was also investigated in cultures of MCF-7 (ER+) and
MDA-MB231 (ER-) BC cells.
The data presented support the potential translational use of
PEG-LPrA2 for prevention and/or treatment of BC. Differential
effects for leptin signaling on the growth of ER+ and ER- BC
cells in vitro have been reported [36,37]. These effects could
be related to leptin-induced levels of aromatase [17,18] and to
ER transactivation [19]. Leptin was therefore expected to have
Figure 3
Effects of leptin inhibition on levels of proliferating cell nuclear antigen and cyclin D1 Effects of leptin inhibition on levels of proliferating cell nuclear antigen and cyclin D1. (a) MCF-7 breast cancer (BC) xenograft and (b) MDA-MB231 
BC xenograft western blot results for proliferating cell nuclear antigen (PCNA) and cyclin D1 in tumor lysates from controls and SCID mice treated 
with leptin signaling antagonist (pegylated leptin peptide receptor antagonist 2 (PEG-LPrA2)). β-Actin was used as a loading control for western blot 
analysis. *P < 0.05, significant difference in mice treated with PEG-LPrA2 with respect to control mice receiving pegylated scrambled peptide. Data 
(mean ± standard error) show representative results (n = 10 tumors/treatment).Breast Cancer Research    Vol 11 No 3    Rene Gonzalez et al.
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stronger effects on the growth of ER+ BC. To investigate this
hypothesis, SCID mice hosting ER+ MCF-7 and ER- MDA-
MB231 BC xenografts were treated with a leptin-signaling
antagonist, PEG-LPrA2.
A n  i m p r e s s i v e  r e d u c t i o n  o f  g r o w t h  o f  E R +  and ER-  BC
xenografts was found after PEG-LPrA2 treatment. Moreover,
both types of human BC xenografts responded to PEG-LPrA2
treatment by reducing the expression of several leptin-tar-
geted molecules. Different growth rates for MCF-7 BC and
MDA-MB231 BC xenografts in control mice (receiving Sc-
PEG) were detected after 14 days of treatment. Although the
exact reasons for this finding are unknown, it could be related
to the boost of estradiol after re-emplacing the estradiol cap-
sules in ovariectomized mice hosting MCF-7 BC.
The present data further support the idea that leptin signaling
plays an important role in BC development and/or progression
that may be mechanistically linked to leptin-mediated upregu-
lation of pro-angiogenic and pro-proliferative factors. Inhibition
of leptin signaling, however, more markedly reduced the
growth and expression of leptin-related molecules in MCF-7
BC in comparison with MDA-MB231 BC xenografts. Specifi-
cally, leptin signaling inhibition decreased the levels of VEGF
and leptin and their respective receptors within both BC
xenograft types. MDA-MB231 BC xenografts had higher lev-
els of VEGF and leptin than MCF-7 BC xenografts. The inhibi-
tion of leptin signaling therefore almost completely blocked
VEGF expression and reduced leptin levels within MCF-7 BC.
Reasons for the relative high levels of human leptin found in
plasma of treated mice hosting MCF-7 are unknown but could
be related to cross-reactivity of ELISA antibodies with leptin
peptide receptor antagonist 2 (composed by a stretch the
Figure 4
Leptin-inhibition effects on levels of human and mouse VEGF/VEGFR2 and leptin/OB-Rb in SCID mice Leptin-inhibition effects on levels of human and mouse VEGF/VEGFR2 and leptin/OB-Rb in SCID mice. Human and mouse vascular endothelial 
growth factor (hVEGF and mVEGF) and human and mouse leptin (hLeptin and mLeptin) concentrations in tumor lysates and plasma, and western 
blot results for human VEGF and vascular endothelial growth factor receptor type 2 (VEGFR2) (mouse and human) and for human leptin receptor 
(OB-Rb) in MCF-7 breast cancer (BC) (a,c) and MDA-MB231 BC (b,d), respectively. β-Actin was used as a loading control for western blot analy-
sis. *P < 0.05 and **P < 0.01, significant difference in mice treated with pegylated leptin peptide receptor antagonist 2 (PEG-LPrA2) with respect to 
control mice receiving pegylated scrambled peptide, respectively. Data (mean ± standard error) show representative results (n = 10 tumors/treat-
ment). MT, mammary tumor.Available online http://breast-cancer-research.com/content/11/3/R36
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human leptin molecule). The ovariectomized mice hosting
MCF-7 showed higher accumulation of abdominal fat than
those nonovariectomized hosting MDA-MB231 BC cells.
PEG-LPrA2 has an enhanced half-life (60 hours) compared
with leptin (approximately 1 hour). Preliminary pharmacokinet-
ics studies showed that PEG-LPrA2 was found at a higher
concentration in mouse adipose tissue (RR Gonzalez, unpub-
lished data).
Leptin is an upstream regulator of angiogenic molecules
[21,24,32,33,38-40]. Leptin peptide receptor antagonist 2
treatment decreased the levels of leptin-induced angiogenic
molecules in mouse tumors and human endometrial cancer
cells [3,24]. These data suggest that the inhibition of leptin
signaling negatively impacted tumor growth by decreasing
leptin-induced expression of several factors implicated in epi-
thelial cell proliferation, adhesion, inflammation and angiogen-
esis; for example, β3-integrin [38,41,42], metalloproteinases
[43], leukemia inhibitory factor, leukemia inhibitory factor
receptor, IL-1, IL-1 receptor (IL-1R tI), and IL-1 receptor antag-
onist [32,34,38-40]. Many genes regulated by leptin in MCF-
7 cells are related to growth factors, cell cycle regulators,
extracellular matrix, metastasis (that is, cyclin D, cyclin G, cyc-
lin-dependent kinase 2, p21, p27, p16, connective tissue
growth factor, villin 2, and basigin), and anti-apoptosis (BCL2
and surviving) [28]. In line with this notion, the mice treated
with PEG-LPrA2 had diminished expression of VEGF/
VEGFR2, OB-R, leptin, IL-1R tI, PCNA and cyclin D1.
Even though normal mammary cells express leptin and OB-R,
abnormal high levels of leptin/OB-R expression are found in
BC that is related to both the metastasis and lower survival
rates [1,11,13]. The reduction of leptin and OB-R levels in ER-
BC and ER+ BC after PEG-LPrA2 treatment could therefore
negatively impact on leptin's actions within BC and may have
a potential value as subrogate markers to assess the efficacy
of leptin-signaling inhibition as a novel anticancer therapy.
It is known that tumor stroma (noncancerous cells; that is,
fibroblasts, immune and endothelial cells) could play a role in
promoting tumor growth [44]. To gain further insight into
mechanisms of leptin-induced tumor growth and angiogenesis
in BC, the levels of mouse VEGF and leptin in tumor stroma
were investigated. Interestingly, stroma from MCF-7 BC
xenografts had higher levels of mouse VEGF and leptin than
those found in stroma from MDA-MB231 BC xenografts.
These data were in contrast to the higher levels of human
V E G F  s e c r e t e d  b y  M D A - M B 2 3 1  B C  i n  c o m p a r i s o n  w i t h
VEGF levels secreted by MCF-7 BC xenografts. These data
suggest that MCF-7 ER+ BC differentially secrete factors
inducing the expression of VEGF and leptin by tumor stroma
compared with MDA-MB231 BC. Factors secreted by MCF-7
BC could further promote via tumor-stroma angiogenesis and,
consequently, tumor growth [44]. Remarkably, PEG-LPrA2
treatment decreased levels of human and mouse VEGF and
leptin in MCF-7 ER+ BC. This could explain in part the higher
effectiveness of PEG-LPrA2 treatment in reducing tumor
growth in MCF-7 ER+. Importantly, PEG-LPrA2 treatment did
not affect mouse leptin levels in plasma, suggesting that this
compound did not interfere with the systemic leptin metabo-
lism. Indeed, no significant effects on body weight or carcass
weight were found between mice hosting the same type of BC
xenografts and treated with PEG-LPrA2 or Sc-PEG control.
The role of leptin signaling in the regulation of VEGF and
VEGFR2 by MCF-7 and MDA-MB231 cancer cells was further
Table 1
Treatment effects on mouse energy balance and growth of MCF-7 and MDA-MB231 breast cancer xenografts
MCF-7 (estrogen-receptor-positive) xenografts MDA-MB231 (estrogen-receptor-negative) xenografts
PEG-LPrA2 Sc-PEG PEG-LPrA2 Sc-PEG
Initial food intake (g/day) 2.2 ± 0.7 2.2 ± 0.4 2.6 ± 0.6 2.4 ± 0.2
Final food intake (g/day) 2.9 ± 0.5 2.8 ± 0.4 2.9 ± 0.6 2.9 ± 0.4
Food intake change (g/day) +0.7 +0.6 +0.3 +0.5
Initial body weight (g) 19.7 ± 2.0 19.6 ± 0.7 18.8 ± 0.7 19.2 ± 0.3
Final body weight (g) 23.9 ± 0.7 24.9 ± 1.3 19.3 ± 1.3 20.0 ± 1.4
Body weight change (g) +4.2 +5.3 +0.5 +0.8
Carcass weight (g) 17.1 ± 1.0 17.9 ± 0.7 14.2 ± 1.2* 14.6 ± 0.2*
Final tumor volume (mm3) 20.5 ± 5.0 >1,100 ± 180 210 ± 29 430 ± 45
n 10 10 10 10
Data expressed as mean ± standard deviation (n = 10 tumors/breast cancer type/treatment). *P < 0.05, significant difference in carcass weight of 
mice hosting MDA-MB-231 breast cancer xenografts treated with pegylated leptin peptide receptor antagonist 2 (PEG-LPrA2) or pegylated 
scrambled peptide (Sc-PEG) with respect to mice hosting MCF-7 breast cancer xenografts (n = 10 tumors/treatment).Breast Cancer Research    Vol 11 No 3    Rene Gonzalez et al.
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studied in vitro. Leptin and VEGF basal levels were higher in
MDA-MB231 compared with those from MCF-7 cells, but lep-
tin increased the levels of secreted protein VEGF only in MCF-
7 cells. In contrast, VEGF mRNA expression was upregulated
by leptin in both cell types. This is probably due to the consti-
tutive expression of VEGF and/or the autocrine and paracrine
actions of leptin in MDA-MB231 cells. Remarkably, leptin-
induced effects on VEGF and VEGFR2 levels were abrogated
by co-incubation of cells with PEG-LPrA2. Data from in vitro
studies correlate with findings from BC xenografts. These data
further suggest that leptin could induce VEGF/VEGFR2
expression in BC.
Taken together, the present data support a role for leptin as a
tumor growth factor. Moreover, the leptin effect is probably
mediated via several angiogenic and pro-proliferative mole-
cules in BC. The increased susceptibility of ER+ BC compared
with ER- BC to the negative impact of PEG-LPrA2 leptin-sign-
aling inhibition could partially be related to differential mecha-
nisms for leptin regulation of VEGF/VEGFR2 in the BC cells
used. In addition, it cannot be ruled out that leptin-signaling
crosstalk could activate other signaling mechanisms related to
essential factors for BC growth; that is, insulin-like growth fac-
tor [45] and human epidermal growth factor receptor-2
(HER2/neu; erbB2) [46]. HER2/neu increases the levels of
Figure 5
Leptin effects on VEGF and VEGFR2 protein and mRNA in MCF-7 and MDA-MB231 cultures Leptin effects on VEGF and VEGFR2 protein and mRNA in MCF-7 and MDA-MB231 cultures. Vascular endothelial growth factor (VEGF) protein 
and mRNA and vascular endothelial growth factor receptor type 2 (VEGFR2) protein and mRNA levels in MCF-7 breast cancer (BC) (a,c) and MDA-
MB231 BC cells (b,d), respectively. The cells were cultured for 48 hours in medium containing leptin (0 to 6.25 nM, equivalent to 10 to 100 ng/ml) 
and/or pegylated leptin peptide receptor antagonist 2 (PEG-LPrA2) (3 μM). Levels of VEGF protein in the supernatants determined by ELISA. Levels 
of VEGFR2 protein in cell lysates determined by immunoprecipitation/western blot. β-Actin used as loading control for western blot determinations. 
VEGF and VEGFR2 mRNA determined by real-time RT-PCR and expressed as relative values to basal conditions. All data were derived from a mini-
mum of three independent experiments using different cell preparations. *P < 0.05, comparing levels of basal cells with treated cells.Available online http://breast-cancer-research.com/content/11/3/R36
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the anti-apoptotic protein Bcl-2 [47] and pro-proliferative mol-
ecules, the cyclin-dependent kinase inhibitor p27Kip1 and the
cell cycle regulatory protein cyclin D1 [48]. HER2/neu shows
moderate to low expression by MCF-7 and MDA-MB231 [46],
but the HER2/neu-leptin signaling link can further increase the
levels of pro-survival factors [26,27] and pro-proliferative fac-
tors [24]. Off-target effects of PEG-LPrA2 treatment therefore
cannot be excluded from the interpretation of data. Neverthe-
less, these data suggest that targeting leptin/OB-R functions
may negatively impact tumor growth, angiogenesis, apoptosis,
and expression of inflammation-related factors and could
impair leptin-growth promoter-factor crosstalk in human BC.
Our present findings may have particular importance for
designing new therapies for BC and other cancer types (that
is, endometrial cancer, colon cancer, prostate cancer, and so
forth) where obesity and leptin signaling have also been
related to their incidence and growth [8,23]. Inhibition of leptin
signaling could be especially useful for the treatment of more
aggressive and invasive ER- BC that is currently treated with a
variety of chemotherapeutics with many debilitating side
effects [20]. In contrast, preliminary pharmacokinetic and toxi-
cological studies suggest that the high-molecular-weight
PEG-LPrA2 derivative does not travel through the blood-brain
barrier and therefore it is not bound to hypothalamic OB-R or
accumulated in the central nervous system of mice. This sug-
gests PEG-LPrA2 may not interfere with leptin biological
actions at the hypothalamic level. PEG-LPrA2 shows no detri-
mental effects on the general health status of mice. Indeed,
mice treated for more than 2 months with PEG-LPrA2 showed
no evident toxicity or change in appetite/energy balance, insu-
lin/glucose levels, or general health status (RR Gonzalez,
unpublished data).
Conclusions
Results from the present investigation strongly support the
idea that leptin signaling plays an important role in the estab-
lishment and growth of both human ER+ MCF-7 and ER- MDA-
MB231 BC xenografts. Leptin actions in these tumors are
probably related to leptin-mediated increase in levels of VEGF/
VEGFR2 and OB-R and other leptin-targeted molecules
essential to BC growth. ER+ BC was more responsive, how-
ever, to PEG-LPrA2 mediated inhibition of leptin signaling than
ER- BC. Overall, our data open the possibility that inhibition of
leptin signaling may serve as a novel adjuvant for prevention
and treatment of BC, particularly in populations under higher
risk and exhibiting higher levels of leptin: such as obese and
postmenopausal women. The alarming increase of incidence
of obesity in the western countries emphasizes the importance
of our findings on leptin-signaling inhibition for reduction of
ER+ BC and ER- BC growth.
Competing interests
The authors declare that they have no competing interests.
RRG is an inventor of the Boston Biomedical Research Insti-
tute's patent Leptin Peptide Antagonists (US Patent
7407929, Application No. 10/841,218; International Applica-
tion No. PCT/US 05/15198). No financial benefits have been
derived from this patent.
Authors' contributions
RRG conceived of the study, participated in its design and
coordination, and drafted the manuscript. AW participated in
the animal trials, and helped carry out the immunohistochemi-
cal studies and western blot and ELISA determinations of rel-
evant molecules. YX carried out the molecular genetic studies.
UPS participated in the immunohistochemical studies. DRM
participated in drafting the manuscript. BRR participated in the
design of the study and drafted the manuscript. MLP partici-
pated in the design of the study and drafted the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
The authors thank Dr Tracy R Daniels, University of California, Los Ange-
les, CA, USA for her useful suggestions, Dr Fang Tan, Emory University 
School of Medicine, Atlanta, GA, USA for the donation of primers for 
VEGF and VEGFR2, and Dr Alexander Quarshie, Director Biostatistics 
and Data Management Core, Associate Director, Master of Science in 
Clinical Research Program, Morehouse School of Medicine for his help 
with the statistical analysis.
Funding awarded to RRG includes NIH/NCI 5SC1CA138658-01, NIH/
UAB Breast SPORE Career Development Award, BC 504370 Susan 
G. Komen Foundation for the Cure, the Cancer Research and Preven-
tion Foundation, the Georgia Cancer Coalition Distinguished Cancer 
Scholar Award, CIG-07-114 Consortium for Industrial Collaboration in 
Contraceptive Research (CICCR), and Contraceptive Research and 
Development Program (CONRAD), Eastern Virginia Medical School. 
Funding awarded to DRM includes NIH/HD41749. Other funds were 
from the Morehouse School of Medicine Dean's Fund for Minority Stu-
dent Training, facilities and support services at Morehouse School of 
Medicine (NIH RR03034 and 1C06 RR18386).
References
1. Ishikawa M, Kitayama J, Nagawa H: Enhanced expression of lep-
tin and leptin receptor (OB-R) in human breast cancer.  Clin
Cancer Res 2004, 10:4325-4331.
2. Yuan SS, Tsai KB, Chung YF, Chan TF, Yeh YT, Tsai LY, Su JH:
Aberrant expression and possible involvement of the leptin
receptor in endometrial cancer.  Gynecol Oncol 2004,
92:769-775.
3. Carino C, Olawaiye AB, Cherfils S, Serikawa T, Lynch MP, Rueda
BR, Gonzalez RR: Leptin regulation of pro-angiogenic mole-
cules in benign and cancer endometrial cells.  Int J Cancer
2008, 123:2782-2790.
4. Tartaglia LA: The leptin receptor.  J Biol Chem 1997,
272:6093-6096.
5. Baumann H, Morella KK, White DW, Dembski M, Bailon PS, Kim
H, Lai CF, Tartaglia LA: The full-length leptin receptor has sign-
aling capabilities of interleukin 6-type cytokine receptors.
Proc Natl Acad Sci USA 1996, 93:8374-8378.
6. Pischon T, Nöthlings U, Boeing H: Obesity and cancer.  Proc Nutr
Soc 2008, 67:128-145.
7. Cleary MP, Maihle NJ: The role of body mass index in the rela-
tive risk of developing premenopausal versus postmenopau-
sal breast cancer.  Proc Soc Exp Biol Med 1997, 216:28-43.
8. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Over-
weight, obesity, and mortality from cancer in a prospectively
studied cohort of U.S. adults.  N Engl J Med 2003,
348:1625-1638.Breast Cancer Research    Vol 11 No 3    Rene Gonzalez et al.
Page 12 of 12
(page number not for citation purposes)
9. Garofalo C, Surmacz E: Leptin and cancer.  J Cell Physiol 2006,
207:12-22.
10. Vona-Davis L, Rose DP: Adipokines as endocrine, paracrine,
and autocrine factors in breast cancer risk and progression.
Endocr Relat Cancer 2007, 14:189-206.
11. Mantzoros CS, Bolhke K, Moschos S, Cramer DW: Leptin in rela-
tion to carcinoma in situ of the breast: a study of pre-meno-
pausal cases and controls.  Int J Cancer 1999, 80:523-536.
12. Petridou E, Papadiamantis Y, Markopoulos C, Spanos E,
Dessypris N, Trichopoulos D: Leptin and insulin growth factor I
in relation to breast cancer (Greece).  Cancer Causes Control
2000, 11:383-388.
13. Miyoshi Y, Funahashi T, Tanaka S, Taguchi T, Tamaki Y, Shi-
momura I, Noguchi S: High expression of leptin receptor mRNA
in breast cancer tissue predicts poor prognosis for patients
with high, but not low, serum leptin levels.  Int J Cancer 2006,
118:1414-1419.
14. Hu X, Juneja SC, Maihle NJ, Cleary MP: Leptin – a growth factor
in normal and malignant breast cells and for normal mammary
gland development.  J Natl Cancer Inst 2002, 94:1704-1711.
15. Celis JE, Moreira JMA, Cabezón T, Gromov P, Friis E, Rank F, Gro-
mov I: Identification of extracellular and intracellular signaling
components of the mammary adipose tissue and its interstitial
fluid in high risk breast cancer patients. Toward dissecting the
molecular circuitry of epithelial-adipocyte stromal cell interac-
tions.  Mol Cell Proteomics 2005, 4:492-522.
16. Lopez-Tarruella S, Schiff R: The dynamics of estrogen receptor
status in breast cancer: re-shaping the paradigm.  Clin Cancer
Res 2007, 13:6921-6925.
17. Dieudonne MN, Machinal-Quelin F, Serazin-Leroy V, Leneveu MC,
Pecquery R, Giudicelli Y: Leptin mediates a proliferative
response in human MCF-7 breast cancer cells.  Biochem Bio-
phys Res Commun 2002, 293:622-628.
18. Catalano S, Marsico S, Giordano C, Mauro L, Rizza P, Panno ML,
Ando S: Leptin enhances, via AP-1, expression of aromatase in
the MCF-7 cell line.  J Biol Chem 2003, 278:28668-28676.
19. Catalano S, Mauro L, Marsico S, Giordano C, Rizza P, Rago V,
Montanaro D, Maggiolini M, Panno ML, Ando S: Leptin induces,
via ERK1/ERK2 signal, functional activation of estrogen recep-
tor alpha in MCF-7 cells.  J Biol Chem 2004, 279:19908-19915.
20. Shapiro CL, Recht A: Side effects of adjuvant treatment of
breast cancer.  N Engl J Med 2001, 344:1997-2008.
21. Sierra-Honigmann MR, Nath AK, Murakami C, García-Cardeña G,
Papapetropoulos A, Sessa WC, Madge LA, Schechner JS,
Schwabb MB, Polverini PJ, Flores-Riveros JR: Biological action of
leptin as an angiogenic factor.  Science 1998, 281:1683-1686.
22. Okumura M, Yamamoto M, Sakuma H, Kojima T, Maruyama T,
Jamali M, Cooper D, Yasuda K: Leptin and high glucose stimu-
late cell proliferation in MCF-7 human breast cancer cells:
reciprocal involvement of PKC-α and PPAR expression.  Bio-
chim Biophys Acta 2002, 1592:107-116.
23. Chen C, Chang YC, Liu CL, Chang KL, Guo IC: Leptin-induced
growth of human ZR-75-1 breast cancer cells is associated
with up-regulation of cyclin D1 and c-Myc and down-regulation
of tumor suppressor p53 and p21WAF1/CIP1.  Breast Cancer
Res Treat 2006, 98:121-132.
24. Gonzalez RR, Cherfils S, Escobar M, Yoo JH, Carino C, Styer AK,
Sullivan BT, Sakamoto H, Olawaiye A, Serikawa T, Lynch MP,
Rueda BR: Leptin signaling promotes the growth of mammary
tumors and increases the expression of vascular endothelial
growth factor (VEGF) and its receptor type two (VEGF-R2).  J
Biol Chem 2006, 281:26320-26328.
25. McMurtry V, Simeone AM, Nieves-Alicea R, Tari AM: Leptin uti-
lizes Jun N-terminal kinases to stimulate the invasion of MCF-
7 breast cancer cells.  Clin Exp Metastasis 2009, 26:197-204.
26. Fujita Y, Murakami M, Ogawa Y, Masuzaki H, Tanaka M, Ozaki S,
Nakao K, Mimori T: Leptin inhibits stress-induced apoptosis of
T lymphocytes.  Clin Exp Immunol 2002, 128:21-26.
27. Shimabukkuro M, Wang MY, Zhou YT, Newgard CB, Unger RH:
Protection against lipoapoptosis of beta cells through leptin-
dependent maintenance of Bcl-2 expression.  Proc Natl Acad
Sci USA 1998, 95:9558-9561.
28. Perera CN, Chin HG, Duru1 N, Camarillo IG: Leptin-regulated
gene expression in MCF-7 breast cancer cells: mechanistic
insights into leptin-regulated mammary tumor growth and
progression.  J Endocrinol 2008, 199:221-233.
29. Cleary MP, Grande JP, Maihle NJ: Effect of high fat diet on body
weight and mammary tumor latency in MMTV-TGF-α mice.  Int
J Obes Relat Metab Disord 2004, 28:956-962.
30. Cleary MP, Phillips FC, Getzin SC, Jacobson TL, Jacobson MK,
Christensen TA, Juneja SC, Grande SP, Maihle NJ: Genetically
obese MMTV-TGF-α/Lep(ob)Lep(ob) female mice do not
develop mammary tumors.  Breast Cancer Res Treat 2003,
77:205-215.
31. Cleary MP, Juneja SC, Phillips FC, Hu X, Grande JP, Maihle NJ:
Leptin receptor-deficient MMTV-TGF-α/Lepr(db)Lepr(db)
female mice do not develop oncogene-induced mammary
tumors.  Exp Biol Med (Maywood) 2004, 229:182-203.
32. Gonzalez RR, Leavis PC: A peptide derived from the human lep-
tin molecule is a potent inhibitor of the leptin receptor function
in rabbit endometrial cells.  Endocrine 2003, 21:185-195.
33. NIH Image Program   [http://rsb.info.nih.gov/nih-image]
34. Ramos MP, Rueda BR, Leavis PC, Gonzalez RR: Leptin serves as
an upstream activator of an obligatory signaling cascade in the
embryo-implantation process.  Endocrinology 2005,
146:694-701.
35. Analyse-it for Microsoft Excel   [http://www.analyse-it.com]
36. Ray A, Nkhata KJ, Cleary MP: Effects of leptin on human breast
cancer cell lines in relationship to estrogen receptor and HER2
status.  Int J Oncol 2007, 30:1499-1509.
37. Ozbay T, Nahta R: A novel unidirectional cross-talk from the
insulin-like growth factor-I receptor to leptin receptor in
human breast cancer cells.  Mol Cancer Res 2008,
6:1052-1058.
38. Gonzalez RR, Rueda BR, Ramos MP, Littell RD, Glasser S, Leavis
PC: Leptin-induced increase in leukemia inhibitory factor and
its receptor by human endometrium is partially mediated by
interleukin 1 receptor signaling.  Endocrinology 2004,
145:3850-3857.
39. Styer AK, Sullivan BT, Puder M, Arsenault D, Petrozza JC, Seri-
kawa T, Chang S, Hasan T, Gonzalez RR, Rueda BR: Ablation of
leptin signaling disrupts the establishment, development of
and maintenance of endometriosis-like lesions in a murine
model.  Endocrinology 2007, 149:506-514.
40. Gonzalez RR, Leary K, Petrozza JC, Leavis PC: Leptin regulation
of the interleukin-1 system in human endometrial cells.  Mol
Hum Reprod 2003, 9:151-158.
41. Gonzalez RR, Leavis PC: Leptin up-regulates β  3-integrin
expression and IL-1β up-regulates leptin and leptin receptor
expression in human endometrial epithelial cell cultures.
Endocrine 2001, 16:21-28.
42. Yang SN, Chen HT, Tsou HK, Huang CY, Yang WH, Su CM, Fong
YC, Tseng WP, Tang CH: Leptin enhances cell migration in
human chondrosarcoma cells through OBRl leptin receptor.
Carcinogenesis 2009, 30:566-574.
43. Gonzalez RR, Devoto L, Campana A, Bischof P: Effects of leptin,
interleukin-1alpha, interleukin-6, and transforming growth fac-
tor-beta on markers of trophoblast invasive phenotype:
integrins and metalloproteinases.  Endocrine 2001,
15:157-164.
44. Zhang B: Targeting the stroma by T cells to limit tumor growth.
Cancer Res 2008, 68:9570-9573.
45. Saxena NK, Taliaferro-Smith L, Knight BB, Merlin D, Anania FA,
O'Regan RM, Sharma D: Bidirectional crosstalk between leptin
and insulin-like growth factor-I signaling promotes invasion
and migration of breast cancer cells via transactivation of epi-
dermal growth factor receptor.  Cancer Res 2008,
68:9712-9722.
46. Eisenberg A, Biener E, Charlier M, Krishnan RV, Djiane J, Herman
B, Gertler A: Transactivation of erbB2 by short and long iso-
forms of leptin receptors.  FEBS Lett 2004, 565:139-142.
47. Milella M, Trisciuoglio D, Bruno T, Ciuffreda L, Mottolese M, Cian-
ciulli A, Cognetti F, Zangemeister-Wittke U, Del Bufalo D, Zupi G:
Trastuzumab down-regulates Bcl-2 expression and potenti-
ates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense
oligonucleotides in HER-2 gene–amplified breast cancer cells.
Clin Cancer Res 2004, 10:7747-7756.
48. Lenferink AEG, Busse D, Flanagan WM, Yakes FM, Arteaga CL:
ErbB2/neu kinase modulates cellular p27Kip1 and cyclin D1
through multiple signaling pathways.  Cancer Res 2001,
61:6583-6591.